SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

INBX

Inhibrx Biosciences, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 10h ago SEC0001193805-26-001466
Passive stake amendment
Actionable Insight • Neutral

Monitor whether Schonfeld continues to increase its passive stake or converts to a 13D (activist) filing. The increase to 6.47% from a prior 5%+ stake suggests growing passive interest, but the passive filing indicates no intent to influence control.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

INBX drug pipeline →

ozekibart

▲ Bullish Named in this SC 13G/A
Impact
Phase
Filed/PDUFA (BLA accepted by FDA)
Time to market
PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
Next catalyst
PDUFA date · Apr 14, 2027 148d

What to watchThe next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Schonfeld Strategic Advisors LLC filed an amended Schedule 13G disclosing a passive stake of 952,959 shares (6.47%) in Inhibrx Biosciences as of September 30, 2026. This is an increase from the prior initial filing, which showed a 5%+ stake, but the exact prior share count is not provided in the current filing. The filing coincides with Inhibrx's Q3 2026 earnings release, which reported a net loss of $38.7 million and cash of $199.5 million.

Key Financial Metrics

Stake
6.47%
Investor
Schonfeld Strategic Advisors LLC
Investor Type
hedge fund

Key Facts

  • Schonfeld Strategic Advisors LLC disclosed beneficial ownership of 952,959 shares of Inhibrx common stock as of September 30, 2026.
  • The stake represents 6.47% of shares outstanding, based on 14,717,660 shares outstanding as of August 7, 2026.
  • This is an amendment to a prior Schedule 13G filing (initial filing on August 14, 2026).
  • Schonfeld is a passive investment adviser filing under Rule 13d-1(b).
  • The filing was made on the same day as Inhibrx's Q3 2026 earnings release.

Financial Impact

Schonfeld holds 952,959 shares; at a $1.3B market cap (~$88 per share), the stake is valued at approximately $84 million.

ownership_percentage

Risk Factors

  • Schonfeld could later convert to an activist 13D filing, signaling a more active role.
  • The company's cash burn rate ($38.7M net loss in Q3) may require future capital raises, which could dilute existing shareholders.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001193805-26-001466
Document: 0001193805-26-001466-index.html0001193805-26-001466
Document: 0001193805-26-001466.txt0001193805-26-001466

Track record

22 reports on INBX

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +29.54% at T+60 after the Jun 11, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $80.43 Now $77.66 −3.44% settles Feb 12
  2. Nov 13, 20263d ago S-3ASR Bearish 5/10 Entry $82.85 Now $77.66 +6.26% settles Feb 12
  3. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $83.30 Now $77.66 −6.77% settles Feb 12
  4. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $73.29 Now $77.66 +5.96% settles Jan 26
  5. Oct 14, 20264w ago Insider Buy Bullish 4/10 Entry $90.50 Now $77.66 −14.19% settles Jan 12
  6. Sep 28, 20267w ago Insider Cluster Bullish 5/10 Entry $104.83 Now $77.66 −25.92% settles Dec 23
  7. Sep 17, 20268w ago Insider Cluster Bullish 5/10 Entry $109.35 Now $77.66 −28.98% settles Dec 14
  8. Sep 15, 20268w ago Insider Cluster Neutral 4/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
  9. Sep 15, 20268w ago 144 Neutral 2/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
  10. Sep 14, 20269w ago 144 Neutral 2/10 Entry $105.61 Now $77.66 −26.47% settles Dec 9
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026